KRAS and non-small cell lung carcinoma: A meta-analysis of randomized controlled trials (RCTs) comparing anti-PD-(L)1 with chemo-monotherapy for advanced KRAS-mutant NSCLC showed that patients treated with first- or second-line anti-PD-(L)1 with or without chemotherapy had longer OS and PFS than chemotherapy alone [67].